BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 9253354)

  • 1. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism.
    Yamaguchi S; Yachiku S; Morikawa M
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2681-8. PubMed ID: 9253354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and Ki-67 proliferation markers.
    Demıralay E; Altaca G; Demırhan B
    Turk Patoloji Derg; 2011; 27(3):215-20. PubMed ID: 21935871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity.
    Loda M; Lipman J; Cukor B; Bur M; Kwan P; DeLellis RA
    Hum Pathol; 1994 Oct; 25(10):1050-6. PubMed ID: 7927309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear DNA content, S-phase fraction analysis and expression of proliferating cell nuclear antigen (PCNA) of normal and hyperplastic/neoplastic parathyroid glands.
    Suzuki S; Tsuchiya A; Hara K; Abe R
    Fukushima J Med Sci; 1997 Jun; 43(1):41-50. PubMed ID: 9431783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of proliferative activity of glandular cells in hyperfunctioning parathyroid gland using flow cytometric and immunohistochemical methods.
    Xiao-Lin P; Koide N; Kobayashi S; Kobayashi M; Sugenoya A; Iida F; Katsuyama T; Usuda N; Nagata T
    World J Surg; 1996; 20(3):361-6; discussion 367. PubMed ID: 8661846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of flow cytometry in the study of parathyroid hyperplasia and adenomas].
    Mangili F; Sassi I; Schiaffino E; Zogno C; Cantaboni A; Schmid C
    Pathologica; 1992; 84(1092):459-65. PubMed ID: 1491887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism.
    Kifor O; Moore FD; Wang P; Goldstein M; Vassilev P; Kifor I; Hebert SC; Brown EM
    J Clin Endocrinol Metab; 1996 Apr; 81(4):1598-606. PubMed ID: 8636374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on the cellular proliferation and endocrine activity of the parathyroid gland in hyperparathyroidism].
    Hosokawa S
    Nihon Hinyokika Gakkai Zasshi; 1993 Aug; 84(8):1424-31. PubMed ID: 8411803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of patients with secondary hyperparathyroidism.
    Lee HJ; Seo UH; Kim WY; Woo SU; Lee JB
    J Int Med Res; 2013 Feb; 41(1):97-105. PubMed ID: 23569134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parathyroid adenomas and glands in normocalcemic hyperparathyroidism. A light microscopic study.
    Grimelius L; Ejerblad S; Johansson H; Werner I
    Am J Pathol; 1976 Jun; 83(3):475-84. PubMed ID: 937508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 proliferative index in parathyroid adenoma & hyperplasia.
    Karak AK; Sarkar C; Chumber S; Tandon N
    Indian J Med Res; 1997 May; 105():235-8. PubMed ID: 9183080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D receptor and PCNA expression in severe parathyroid hyperplasia of uremic patients.
    Wang X; Sun B; Zhou F; Hu J; Yu X; Peng T
    Chin Med J (Engl); 2001 Apr; 114(4):410-4. PubMed ID: 11780466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroperative evaluation of parathyroid glands using fat stain on frozen sections. Advantages and limitations.
    Farnebo LO; von Unge H
    Acta Chir Scand Suppl; 1984; 520():17-24. PubMed ID: 6209877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical detection of cell cycle regulators, Fhit protein and apoptotic cells in parathyroid lesions.
    Thomopoulou GE; Tseleni-Balafouta S; Lazaris AC; Koutselini H; Kavantzas N; Davaris PS
    Eur J Endocrinol; 2003 Jan; 148(1):81-7. PubMed ID: 12534361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients with primary hyperparathyroidism.
    Letizia C; Ricci F; De Toma G; Cianci R; Alo P; Celi M; Panzironi G; Mingazzini PL; D'Erasmo E; Mazzuoli GF
    Horm Metab Res; 2004 Jul; 36(7):480-4. PubMed ID: 15305232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperfunctional parathyroid glands with 99mTc-MIBI scan: semiquantitative analysis correlated with histologic findings.
    Takebayashi S; Hidai H; Chiba T; Takagi Y; Nagatani Y; Matsubara S
    J Nucl Med; 1999 Nov; 40(11):1792-7. PubMed ID: 10565772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism.
    Tokumoto M; Tsuruya K; Fukuda K; Kanai H; Kuroki S; Hirakata H
    Kidney Int; 2002 Oct; 62(4):1196-207. PubMed ID: 12234290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid glands in uraemic patients with refractory hyperparathyroidism: histopathology and p53 protein expression analysis.
    Martin LN; Kayath MJ; Vieira JG; Nosé-Alberti V
    Histopathology; 1998 Jul; 33(1):46-51. PubMed ID: 9726048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma.
    Tominaga Y; Tsuzuki T; Uchida K; Haba T; Otsuka S; Ichimori T; Yamada K; Numano M; Tanaka Y; Takagi H
    Kidney Int; 1999 Apr; 55(4):1375-83. PubMed ID: 10201002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hyperplasia in multiple parathyroid adenomas.
    Larian B; Alavi S; Roesler J; Namazie A; Blackwell K; Calcaterra TC; Wang MB
    Head Neck; 2001 Feb; 23(2):134-9. PubMed ID: 11303630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.